GlassScriptPhysician profile
Navid Navizadeh
NPI 1588654693
$3,911.19
in general payments reported to CMS, 2019-2025
40 companies · $567 in 2025
The $567 reported for 2025 was more than what 89% of Reproductive Endocrinology providers received nationally (typical 2025 total: $140).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $656 · 2020: $297 · 2021: $542 · 2022: $599 · 2023: $528 · 2024: $722 · 2025: $567.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,817.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,817.19 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $527.53 | 2019-2025 | |
| Exeltis, USA INC. | $510.34 | 2021-2025 | Slynd |
| Mayne Pharma Commercial LLC | $275.17 | 2021-2025 | |
| Agile Therapeutics, INC. | $190.85 | 2021-2024 | Twirla |
| Bayer Healthcare Pharmaceuticals INC. | $184.80 | 2019-2025 | |
| Sumitomo Pharma America, INC. | $184.36 | 2023-2024 | Myfembree |
| Therapeuticsmd, INC. | $181.09 | 2019-2022 | |
| Hologic Sales and Service, LLC | $170.09 | 2019-2025 | Thinprep 2000 Processor, Aptima, Fetal Fibronectin Enzyme Immunoassay |
| Merck Sharp & Dohme LLC | $137.91 | 2019-2024 | Gardasil 9, Gardasil |
| Allergan, INC. | $125.08 | 2019-2020 | |
| Astellas Pharma US INC | $113.61 | 2023-2025 | Veozah |
| Myovant Sciences INC. | $103.51 | 2021-2022 | |
| Pfizer INC. | $92.92 | 2022-2024 | |
| Sage Therapeutics, LLC | $92.34 | 2024-2025 | Zurzuvae |
| Daiichi Sankyo INC. | $90.36 | 2020-2021 |
Show all 40 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Navid Navizadeh listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.